EP2295063A3 - Compositions et leur utilisation pour le traitement de maladies mitochondriales - Google Patents

Compositions et leur utilisation pour le traitement de maladies mitochondriales Download PDF

Info

Publication number
EP2295063A3
EP2295063A3 EP10184919A EP10184919A EP2295063A3 EP 2295063 A3 EP2295063 A3 EP 2295063A3 EP 10184919 A EP10184919 A EP 10184919A EP 10184919 A EP10184919 A EP 10184919A EP 2295063 A3 EP2295063 A3 EP 2295063A3
Authority
EP
European Patent Office
Prior art keywords
treatment
compositions
mammal
administering
mitochondrial diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10184919A
Other languages
German (de)
English (en)
Other versions
EP2295063B1 (fr
EP2295063A2 (fr
EP2295063A8 (fr
Inventor
Reid W Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of EP2295063A2 publication Critical patent/EP2295063A2/fr
Publication of EP2295063A8 publication Critical patent/EP2295063A8/fr
Publication of EP2295063A3 publication Critical patent/EP2295063A3/fr
Application granted granted Critical
Publication of EP2295063B1 publication Critical patent/EP2295063B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
EP10184919.8A 1998-08-31 1999-08-31 Compositions et leur utilisation pour le traitement de maladies mitochondriales Expired - Lifetime EP2295063B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/144,096 US6472378B2 (en) 1998-08-31 1998-08-31 Compositions and methods for treatment of mitochondrial diseases
EP99968207A EP1109453B1 (fr) 1998-08-31 1999-08-31 Compositions et procedes de traitement des maladies mitochondriales

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP99968207.3 Division 1999-08-31
EP99968207A Division EP1109453B1 (fr) 1998-08-31 1999-08-31 Compositions et procedes de traitement des maladies mitochondriales

Publications (4)

Publication Number Publication Date
EP2295063A2 EP2295063A2 (fr) 2011-03-16
EP2295063A8 EP2295063A8 (fr) 2011-05-18
EP2295063A3 true EP2295063A3 (fr) 2011-09-14
EP2295063B1 EP2295063B1 (fr) 2017-04-26

Family

ID=22507021

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99968207A Expired - Lifetime EP1109453B1 (fr) 1998-08-31 1999-08-31 Compositions et procedes de traitement des maladies mitochondriales
EP10184919.8A Expired - Lifetime EP2295063B1 (fr) 1998-08-31 1999-08-31 Compositions et leur utilisation pour le traitement de maladies mitochondriales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99968207A Expired - Lifetime EP1109453B1 (fr) 1998-08-31 1999-08-31 Compositions et procedes de traitement des maladies mitochondriales

Country Status (19)

Country Link
US (5) US6472378B2 (fr)
EP (2) EP1109453B1 (fr)
JP (2) JP4717209B2 (fr)
KR (2) KR20010085746A (fr)
CN (2) CN100361665C (fr)
AU (1) AU753203B2 (fr)
BR (1) BR9913319A (fr)
CA (3) CA2931872C (fr)
CY (1) CY1113610T1 (fr)
DK (1) DK1109453T3 (fr)
ES (1) ES2393065T3 (fr)
HK (1) HK1037303A1 (fr)
HU (1) HU230066B1 (fr)
IL (2) IL141429A0 (fr)
NZ (2) NZ586365A (fr)
PT (1) PT1109453E (fr)
RU (2) RU2279880C2 (fr)
WO (1) WO2000011952A1 (fr)
ZA (1) ZA200101565B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776838B1 (en) * 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20020006913A1 (en) * 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
EP1140104B1 (fr) * 1998-07-31 2007-09-26 Massachusetts Institute of Technology Traitement de la maladie d'alzheimer par augmentation des niveaux de cytidine in vivo
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6878514B1 (en) * 1999-03-30 2005-04-12 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001021208A1 (fr) 1999-09-23 2001-03-29 Juvenon Corporation Supplement nutritionnel fournissant une energie et une endurance accrues
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US7118873B2 (en) 2000-12-12 2006-10-10 The University Of Connecticut Polynucleotides encoding cellular transporters and methods of use thereof
DE10110355A1 (de) 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
WO2002083651A2 (fr) * 2001-04-11 2002-10-24 Queen's University At Kingston Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2448160A1 (fr) * 2001-05-25 2002-12-05 Queen's University At Kingston Beta-acides amines heterocycliques et leur utilisation en tant qu'agents anti-epileptogenes
HU225988B1 (en) * 2001-09-05 2008-02-28 Yamasa Corp Use of cytidine-phosphocholine for producing pharmaceutical compositions for diabetic neuropathy
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
WO2003047558A2 (fr) * 2001-12-03 2003-06-12 Genset S.A. Traitement de troubles du systeme nerveux central a l'aide d'inhibiteurs de d-amino-oxydase et de d-aspartate oxydase
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
JPWO2004006940A1 (ja) * 2002-07-11 2005-11-10 ヤマサ醤油株式会社 薬剤誘発性神経障害用医薬組成物
EP3144009A1 (fr) 2003-02-04 2017-03-22 Cornell Research Foundation, Inc. Utilisations d'un peptide aromatique cationique
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
CA2583087C (fr) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Derives de chromane
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
WO2005032278A1 (fr) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. Coq-10 solubilise
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
CA2547086A1 (fr) * 2003-11-25 2005-06-09 University Of Rochester Composes permettant d'apporter des acides amines ou des peptides a activite antioxydante dans des mitochondries et utilisation desdits composes
EP2633853A1 (fr) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Formulations d'administration à long terme et leurs procédés d'utilisation
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2554166C (fr) 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methodes de reduction de lesions par oxydation
WO2005077040A2 (fr) * 2004-02-11 2005-08-25 Rensselaer Polytechnic Institute Compositions et methodes destinees au traitement de la sclerose laterale amyotrophique (sla)
WO2005112635A2 (fr) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Effets de l'uridine sur la liberation de la dopamine
EP1765075A4 (fr) 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, notamment de l'uridine, utilisees dans des traitements sur des patients atteints de troubles bipolaires
KR100675225B1 (ko) * 2004-06-28 2007-01-26 대림산업 주식회사 차음성능 및 단열성능 향상을 위한 경량벽체 시스템 및 그설치방법
CA2575367A1 (fr) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-bromo-2-oxopropionate de propyle et ses derives utilises comme nouveaux agents anticancereux
EP1784199A4 (fr) 2004-08-11 2010-06-23 Mclean Hospital Corp Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
CN102600199A (zh) * 2004-09-15 2012-07-25 麻省理工学院 含有尿苷的组合物及使用其的方法
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US8415388B2 (en) * 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
EP1865972B1 (fr) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Traitement ou prevention du cancer et de troubles precancereux
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
CA2646106C (fr) 2005-05-06 2014-03-18 University Of Kentucky Research Foundation Nanotubes comme decoupleurs mitochondriaux
AU2006251562B2 (en) * 2005-05-23 2012-03-22 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
PL1888059T3 (pl) 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
US20090298782A1 (en) * 2005-12-20 2009-12-03 University Of Rochester Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof
DK1991225T3 (da) 2006-02-22 2013-12-16 Apotex Technologies Inc Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
KR100801057B1 (ko) * 2006-07-18 2008-02-04 삼성전자주식회사 컬러 보정 블럭을 구비하는 ｃｍｏｓ 이미지 센서 및 그이미지 센싱 방법
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
WO2008116301A1 (fr) 2007-03-28 2008-10-02 Apotex Technologies Inc. Dérivés fluorés de défériprone
US8551452B2 (en) * 2007-11-02 2013-10-08 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
WO2009059414A1 (fr) * 2007-11-09 2009-05-14 Genesis Genomics Inc. Suppression de mutations d'adn mitochondrial entre les résidus 12317-16254 pour une utilisation dans la détection d'un cancer
PT2221296E (pt) 2007-11-28 2012-11-23 Astellas Pharma Inc Composto de indano fundido
RU2446807C2 (ru) * 2007-12-20 2012-04-10 Н.В. Нютрисиа Жидкий продукт, содержащий нуклеотиды/нуклеозиды
WO2009129592A1 (fr) * 2008-04-25 2009-10-29 Apotex Technologies Inc. Formulation liquide de défériprone de goût agréable
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2012531411A (ja) 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
ME01911B (me) 2009-07-03 2014-12-20 Apotex Tech Inc Fluorisani derivati 3-hidroksipiridin-4-ona
US8776268B2 (en) * 2009-12-04 2014-07-15 Harpswell Harmony LLC Hand covering(s) with dispenser and/or receptacle pocket
ES2727859T3 (es) 2011-03-31 2019-10-21 Triplex Therapeutics Inc Compuesto de poliamida y composición farmacéutica para el tratamiento de enfermedades genéticas mitocondriales
WO2013035101A1 (fr) 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions de mitochondries fonctionnelles et leurs utilisations
JP2014527969A (ja) * 2011-09-19 2014-10-23 ジェンシア コーポレイション 改変クレアチン化合物
US10369151B2 (en) 2013-05-24 2019-08-06 Societe Des Produits Nestle S.A. Treatment or prevention of autism disorders using menthol, linalool and/or icilin
KR101636946B1 (ko) * 2013-07-29 2016-07-06 한국생명공학연구원 오로트산을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
CA2978521A1 (fr) 2015-05-29 2016-12-08 National Yang-Ming University Agents nucleosidiques pour la reduction de l'activite deletere de genes contenant une repetition de nucleotide etendue
ES2944551T3 (es) * 2015-06-05 2023-06-22 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Tratamiento de enfermedades mitocondriales
WO2017062992A1 (fr) * 2015-10-08 2017-04-13 Retrotope, Inc. Amélioration de la qualité des mesures d'adn mitochondrial destinées à être utilisées dans l'évaluation de dysfonctionnements mitochondriaux
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
CA3008849A1 (fr) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Derives fluoroalkyle, fluoroalcoxy, phenoxy, heteroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
WO2017123823A1 (fr) * 2016-01-12 2017-07-20 Bioelectron Technology Corporation Inhibiteurs de sulfure:quinone oxydoréductase alkyle, acyle, urée, et aza-uracile
EP3500581A4 (fr) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. Constructions polynucléotidiques
EP3506895A4 (fr) * 2016-09-01 2020-04-15 JDS Therapeutics, LLC Compositions de biotinate de magnésium et méthodes d'utilisation
CN107412731B (zh) * 2017-05-17 2020-06-05 广州弘宝元生物科技有限公司 Ul43蛋白在制备预防和治疗线粒体功能障碍的药物中的应用
WO2019006455A1 (fr) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. Auxiliaires de phosphoramidites chiraux et leurs procédés d'utilisation
CN111094327A (zh) * 2017-08-16 2020-05-01 Lgv1有限公司 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型
KR20200116096A (ko) * 2018-02-01 2020-10-08 웰스태트 테러퓨틱스 코포레이션 우리딘의 전신 전달을 위한 조성물 및 장치
US20210375467A1 (en) * 2018-06-26 2021-12-02 Ribonova Inc. Systems and Methods for Computing Measurements for Mitochondrial Diseases
US20200022432A1 (en) * 2018-07-21 2020-01-23 Sheryl K. Bailey Mobile Pocket Glove and Non-gender Hand Wallet
EP3823640A4 (fr) 2018-07-22 2022-05-18 Minovia Therapeutics Ltd. Thérapie d'augmentation mitochondriale de maladies musculaires
CA3106188A1 (fr) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Therapie d'augmentation mitochondriale avec des cellules souches enrichies avec des mitochondries fonctionnelles
ES2889587T3 (es) * 2019-04-18 2022-01-12 Simo Rasi Composición para su uso en la prevención o reducción del estrés oxidativo y de enfermedades neurodegenerativas
EP3970713A1 (fr) 2020-09-16 2022-03-23 GV Squared S.r.l. Composition pharmaceutique comprenant de l'uridine et du pyruvate pour réguler la prolifération, l'activité et la survie des cellules immunitaires
EP4225322A1 (fr) * 2020-10-09 2023-08-16 Adarx Pharmaceuticals, Inc. Composés dérivés de n-acétylgalactosamine (galnac) et oligonucléotides
US20240115592A1 (en) * 2020-12-28 2024-04-11 Yamasa Corporation PGC-1alpha EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT AND MITOCHONDRIA ACTIVATING AGENT
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
CN113413394B (zh) * 2021-07-27 2022-07-01 陈玉松 5’-单磷酸核苷酸及其混合物在制备改善线粒体功能药物或食品中的应用
CN115737666B (zh) * 2022-11-24 2024-03-26 暨南大学 尿苷二磷酸葡萄糖在制备延缓衰老产品中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817877A (en) * 1957-01-30 1959-08-06 Ici Ltd New pyrimidine derivatives
JPS60126221A (ja) * 1983-12-14 1985-07-05 Toyama Chem Co Ltd 抗腫瘍組成物
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
WO1986003678A1 (fr) * 1984-12-20 1986-07-03 Memorial Hospital For Cancer And Allied Diseases Composition et procede de traitement de tumeurs avec de l'udpg
US4600573A (en) * 1983-01-17 1986-07-15 Research Corporation Compositions and method for alleviating the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea
US4789666A (en) * 1985-07-05 1988-12-06 Bioresearch Spa Cytidine-diphosphocholine salts, particularly suitable for oral use
EP0462075A2 (fr) * 1990-06-13 1991-12-18 POLIFARMA S.p.A. Utilisation de l'uridine pour le traitement pharmacologique des complications périphériques du diabète
WO1994026761A1 (fr) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Traitement de la toxicite des agents chimioterapeutiques et des agents antiviraux avec des nucleosides de pyrimidine acyles
US5583117A (en) * 1987-10-28 1996-12-10 Pro-Neuron, Inc. Acylated uridine and cytidine for elevating tissue uridine and cytidine
WO1997045127A1 (fr) * 1996-05-28 1997-12-04 Polifarma S.P.A. Agent actif therapeutique comprenant de l'uridine pour le traitement de troubles neurodegeneratifs
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (fr) 1969-08-06 1972-11-22
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
IT1248528B (it) * 1991-06-21 1995-01-19 Pierrel Spa Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
DE69333575T2 (de) 1992-05-28 2005-08-25 Centre For Molecular Biology And Medicine, Richmond Quinone-derivate zur verbesserung der zellulare bioenergie
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
CN1156409A (zh) * 1994-07-01 1997-08-06 普罗神经细胞有限公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
ATE332127T1 (de) 1994-11-08 2006-07-15 Avicena Group Inc Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US5906996A (en) * 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
EP1140104B1 (fr) 1998-07-31 2007-09-26 Massachusetts Institute of Technology Traitement de la maladie d'alzheimer par augmentation des niveaux de cytidine in vivo
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US20040224920A1 (en) 1999-02-23 2004-11-11 The Regents Of The University Of California Methods of treatment of mitochondrial disorders
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
ITMI20020809A1 (it) * 2002-04-17 2003-10-17 Univ Degli Studi Milano Metodo per la selezione di composti utili nel trattamento della coreadi huntington
JP4243830B2 (ja) 2002-10-18 2009-03-25 セイコーエプソン株式会社 定着装置、およびそれを用いた画像形成装置

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817877A (en) * 1957-01-30 1959-08-06 Ici Ltd New pyrimidine derivatives
US4600573A (en) * 1983-01-17 1986-07-15 Research Corporation Compositions and method for alleviating the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea
JPS60126221A (ja) * 1983-12-14 1985-07-05 Toyama Chem Co Ltd 抗腫瘍組成物
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
WO1986003678A1 (fr) * 1984-12-20 1986-07-03 Memorial Hospital For Cancer And Allied Diseases Composition et procede de traitement de tumeurs avec de l'udpg
US4789666A (en) * 1985-07-05 1988-12-06 Bioresearch Spa Cytidine-diphosphocholine salts, particularly suitable for oral use
US5583117A (en) * 1987-10-28 1996-12-10 Pro-Neuron, Inc. Acylated uridine and cytidine for elevating tissue uridine and cytidine
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
EP0462075A2 (fr) * 1990-06-13 1991-12-18 POLIFARMA S.p.A. Utilisation de l'uridine pour le traitement pharmacologique des complications périphériques du diabète
WO1994026761A1 (fr) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Traitement de la toxicite des agents chimioterapeutiques et des agents antiviraux avec des nucleosides de pyrimidine acyles
WO1997045127A1 (fr) * 1996-05-28 1997-12-04 Polifarma S.P.A. Agent actif therapeutique comprenant de l'uridine pour le traitement de troubles neurodegeneratifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CACABELOS R; CAAMANO J; GOMEZ M J; FERNANDEZ-NOVOA L; FRANCO-MASIDE A; ALVAREZ X A: "Therapeutic effects of CDP-choline in Alzheimer's disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES; THE NEUROBIOLOGY OF ALZHEIMER'S DISEASE, 1996, pages 399 - 403, XP008065562 *
DATABASE WPI Week 198533, Derwent World Patents Index; AN 1985-200308, XP002655975 *
DATABASE WPI Week 198542, Derwent World Patents Index; AN 1985-260426, XP002655974 *
PECORI GIRALDI J; GRECHI G; APPIOTTI A; MANFREDI A: "Systemic administration of a neurotrophic drug in the complementary treatment of glaucomatous optic neuropathy", NEW TRENDS IN OPHTHALMOLOGY, vol. 9, no. 2, 1994, pages 85 - 91, XP008065559 *

Also Published As

Publication number Publication date
EP1109453A1 (fr) 2001-06-27
CN1636572A (zh) 2005-07-13
BR9913319A (pt) 2001-05-22
EP2295063B1 (fr) 2017-04-26
US20050203066A1 (en) 2005-09-15
CA2341700A1 (fr) 2000-03-09
KR20070091683A (ko) 2007-09-11
NZ597270A (en) 2013-06-28
IL141429A (en) 2013-10-31
DK1109453T3 (da) 2012-11-19
CA2696878C (fr) 2016-08-16
CA2931872A1 (fr) 2000-03-09
KR20010085746A (ko) 2001-09-07
US8067392B2 (en) 2011-11-29
JP4717209B2 (ja) 2011-07-06
RU2279880C2 (ru) 2006-07-20
ZA200101565B (en) 2002-05-15
EP1109453A4 (fr) 2006-11-02
HU230066B1 (hu) 2015-06-29
US20010016576A1 (en) 2001-08-23
US6472378B2 (en) 2002-10-29
CN1328417A (zh) 2001-12-26
US20110144051A1 (en) 2011-06-16
CY1113610T1 (el) 2016-06-22
HUP0103255A2 (hu) 2002-04-29
HK1037303A1 (en) 2002-02-08
US7582619B2 (en) 2009-09-01
RU2006108077A (ru) 2007-09-20
AU753203B2 (en) 2002-10-10
EP2295063A2 (fr) 2011-03-16
HUP0103255A3 (en) 2003-01-28
PT1109453E (pt) 2012-11-05
US20010005719A1 (en) 2001-06-28
CN1636572B (zh) 2012-09-05
CA2341700C (fr) 2010-06-15
JP2010195837A (ja) 2010-09-09
US6956028B2 (en) 2005-10-18
CN100361665C (zh) 2008-01-16
ES2393065T3 (es) 2012-12-18
US20070010479A1 (en) 2007-01-11
CA2931872C (fr) 2019-08-06
NZ586365A (en) 2012-01-12
IL141429A0 (en) 2002-03-10
AU6021999A (en) 2000-03-21
CA2696878A1 (fr) 2000-03-09
JP2002523434A (ja) 2002-07-30
KR101208016B1 (ko) 2012-12-04
EP2295063A8 (fr) 2011-05-18
EP1109453B1 (fr) 2012-07-25
WO2000011952A1 (fr) 2000-03-09

Similar Documents

Publication Publication Date Title
EP2295063A3 (fr) Compositions et leur utilisation pour le traitement de maladies mitochondriales
WO2001072721A3 (fr) Methodes et compositions synergetiques destinees au traitement du cancer
CA2388939A1 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
CA2334267A1 (fr) Utilisation de peg-ifn-alpha et de ribavirine pour traiter l'hepatite c chronique
DE69007319T2 (de) Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.
WO2005047244A3 (fr) Inhibition de recepteur fgfr3 et traitement de myelome multiple
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
WO2001024763A3 (fr) Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO2002076472A3 (fr) Combinaisons pharmaceutiques destinees au traitement du cancer
BR9607109A (pt) Emprego de 5'nucleosídeos substituidos para a formação de resisténcia no tratamento de citostáticos e medicamentos contendo estes nucleosídeos
WO2003061566A3 (fr) Combinaison anticancereuse et son utilisation
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
EP1177791A3 (fr) Utilisation d'inhibiteur de la glycogen phosphorylase pour inhiber la croissance de tumeurs
CA2401191A1 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
HK1041209A1 (zh) 加強藥物療效的成份及方法
WO2005025501A3 (fr) Co-administration de polysaccharide avec un agent chimiotherapeutique pour le traitement du cancer
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO2006050381A3 (fr) Composition antivirale
CA2288059A1 (fr) Procede de traitement des tumeurs malignes
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
WO2002076393A3 (fr) Agents antiangionenes, antitumoraux, et chimiopreventifs
IL127851A0 (en) Inhibition of TNF activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100930

AC Divisional application: reference to earlier application

Ref document number: 1109453

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WELLSTAT THERAPEUTICS CORPORATION

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146532

Country of ref document: HK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20110808BHEP

Ipc: A61K 31/7072 20060101ALI20110808BHEP

Ipc: A61K 31/7068 20060101AFI20110808BHEP

17Q First examination report despatched

Effective date: 20120504

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161124

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1109453

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 887284

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69945741

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170426

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 887284

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170727

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69945741

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69945741

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: HK

Ref legal event code: WD

Ref document number: 1146532

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

26N No opposition filed

Effective date: 20180129

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180301

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426